CoChat
Cited by 217

The DOI matches its Crossref record.

Macrolide – induced clinically relevant drug interactions with cytochrome P‐450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin

Open access
Westphal, Jean Frédéric · 2000 · British Journal of Clinical Pharmacology

Abstract

The oxidative phase of the biotransformation of drugs is a function of hepatic or intestinal cytochromes P-450, also called the mixed-function oxidase system. Three families of cytochromes – CYP1, CYP2, and CYP3 – perform the oxidative metabolism of drugs in humans. Within these families, five isoforms – CYP 1A2, CYP 2C9, CYP 2C19, CYP 2D6, and CYP 3A4 – account for nearly all the side-effects related to drug interactions [1, 2]. The ability of macrolide antibiotics to interact with the biotransformation of some other drugs has been widely recognized, mostly with erythromycin and troleandomycin because these compounds have been marketed decades ago. Macrolides can induce their own hepatic biotransformation into nitrosoalkanes. These metabolites are derived from the metabolic oxidation of the –N(CH3)2 group of the antibiotic to the corresponding –NO group. Nitrosoalkanes subsequently form inactive CYP 3A4-iron-metabolite complexes ( Figure 1) resulting in inhibition of the CYP 3A4-mediated catalytic activity [3]. This mechanism accounts for most of the drug interactions produced by macrolides [4]. Metabolism of macrolides. Macrolides differ in their abilities to bind to and inhibit the cytochrome P-450 isoform CYP 3A4 [3, 5–7]. These differences prompted von Rosenstiel & Adam [8] to classify macrolide antibiotics into three groups on the basis of data provided by in vitro experiments: • Group 1 agents include erythromycin and troleandomycin. Both drugs bind strongly to and inhibit markedly CYP 3A4. Since troleandomycin was withdrawn from the market many years ago, this drug will not be discussed further in the present paper; • Clarithromycin belongs to Group 2 agents. This drug exhibits lower affinity for CYP 3A4 as compared with erythromycin, and form complexes to a lesser extent; • Group 3 include azithromycin and dirithromycin. These compounds have been shown to interfere poorly with cytochrome P-450 system in vitro. Clarithromycin has recently appeared to be similar to erythromycin in some drug interactions (e.g. with psychotropic agents), on the basis of the results of some clinical studies. Furthermore, a number of recent clinical case reports demonstrate that azithromycin and dirithromycin still exhibit some potential for drug interactions, although to a much lesser extent than that with erythromycin. The discrepancy between what is expected from in vitro data and what may be observed in clinical practice underscores the well-known interindividual variability in the extent of cytochrome P-450 catalytic activity (as much as 10- to 20-fold). This pattern provides some explanation for why some patients appear to be more susceptible than others to a given drug–drug interaction. It is now clear that the heterogeneity among patients in the ability to perform P-450 metabolism of some drugs is largely the result of genetic factors [1]. Aside from the drug-induced induction/inhibition enzymatic processes, some other nongenetic factors probably contribute to interpatient differences in the liver content or activity of individual P-450: • for example, dietary differences may contribute significantly [9, 10]. • CYP 3A4 activity may be non specifically depressed by debilitation or disease, e.g. liver cirrhosis [11] or celiac disease [12]. • importantly the infectious process by itsef can affect the activity of CYP; viral or bacterial pulmonary infections have been shown to depress CYP activity. In a sequential study conducted in 14 patients with fever and clinical pneumonia, antipyrine clearance was on average impaired by 36% [13]. Antipyrine elimination proceeds almost exclusively through hepatic biotransformation, and its metabolites are formed by at least 6 hepatic cytochrome P-450 isoforms, namely CYP 1A2, CYP 2B6, CYP 2C8, CYP 2C9, CYP 2C18 and CYP 3A4 [14]. Hence, the infection is likely to induce global inhibition of cytochrome P-450 catalytic activities. This stems probably from the release of endotoxin or interferon during the infection [15, 16]. Conceivably, the combination of interferon- or endotoxin-related CYP depression and the macrolide-induced inhibition of the CYP 3A4 isoform might result in an enhanced metabolic interaction. An additional factor that may contribute to individual variability in the extent of drug interactions of pharmacokinetic type is the involvement of P-glycoprotein (P-gp). Drug-induced changes in expression of this protein may overlap changes at the level of CYP catalytic activities. P-gp is an ATP-dependent efflux drug transporter that is constitutively expressed in normal tisues including the gastrointestinal epithelium, the canalicular membrane of the liver, the kidney and capillary endothelial cells in the central nervous system [17, 18]. P-gp appears to play a key role in absorption, distribution and elimination of many anticancer agents as well as other drugs such as digoxin or cyclosporin [19, 20]. Many P-gp inhibitors are also inhibitors of CYP 3A [21]. However, Wandel

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2125.2000.00261.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 217

Metadata

Authors
Westphal, J. F.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2000-10
Volume
50
Issue
4
Pages
285-295
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1531474084
Cited by
217
References
0
FWCI
4.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Macrolide – induced clinically relevant drug interactions with cytochrome P‐450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. https://app.cochat.ai/papers/10.1046/j.1365-2125.2000.00261.x
The paper
Westphal, J. F. (2000). Macrolide – induced clinically relevant drug interactions with cytochrome P‐450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.1365-2125.2000.00261.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.